Celine M. Clive (Interpharm/CRC Press, 2004), 288 pages with CD-ROM, hardcover, ISBN: 0849321816, $229.95
Handbook of SOPs for Good Clinical Practice, Second edition
Celine M. Clive (Interpharm/CRC Press, 2004), 288 pages with CD-ROM, hardcover, ISBN: 0849321816, $229.95
Handbook of SOPs for Good Clinical Practice was prepared as a tool to aid organizations in the development of standard operating procedures (SOPs) for groups involved in the conduct of clinical trials. It is a revision of an earlier version of the handbook prepared by different authors. The book is divided into three sections covering SOPs for the sponsor and/or contract research organization, the study site, and the institutional review board (IRB). In addition to providing templates of standard SOPs that can be customized and adapted for use, the book also contains examples of common forms and checklists that are useful in the implementation and execution of the SOPs. Another advantage of the book is the inclusion of a CD-ROM that contains an electronic copy of all of the templates and forms for ease in preparing the customized versions for personal use.
The book is a very basic resource and contains only the minimum set of SOPs that an organization would need to cover activities related to the execution of a clinical trial. It also lacks any kind of explanation of the origin or genesis of some of the SOPs and the roles of persons described. And as a result, the book might be a better resource if accompanied by some discussion of what GCP is, how it is applied, and the role of different individuals. The book also makes numerous assumptions without explanation regarding the organization and role of individuals involved in the clinical studies. Many of the SOPs contain statements regarding GCP practices that are not supported, nor consistent with most interpretations of GCP. For example, the SOP for the Sponsor regarding study clinical supplies refers to interactions with the site pharmacist only. This assumes that all sites have a pharmacist on staff. The SOP discusses the role of the monitor, pharmacist, and coordinator, but never mentions the role of the Principal Investigator-who is ultimately responsible for the clinical supplies, regardless of whether there is a site pharmacist available. The SOP regarding obtaining informed consent directs the coordinator to contact the IRB and ensure that the draft is compliant with the regulations. This is clearly a task that is the regulatory responsibility of the Investigator. This SOP also indicates that a witness is required for informed consent when a non-English speaking person signs the consent, also not required by GCP.
Despite some of these deficiencies, Handbook of SOPs for Good Clinical Practice is a good beginner's reference for someone who needs to prepare a set of SOPs.
Michael R. Hamrell,PhD, is with Moriah Consultants, Yorba Linda, CA, email: michael@moriahconsultants.com.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.